NEW YORK (GenomeWeb News) – Evotec has agreed to provide Biogen Idec with high-throughput screening and assay development services for a particular target, Evotec said today.
Evotec said that it will use its protein production, assay development, and screening technologies to identify drug candidates for Biogen Idec. The agreement also includes an option to cover further targets.
"We believe that the quality of future drug candidates is very much dependent on the identification of high quality starting points," Evotec's Executive VP of Business Development, Mark Ashton, said in a statement.
Financial terms of the agreement were not released.